Combination therapy for the treatment of hepatitis C in the veteran population: Higher than expected rates of therapy discontinuation

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 6, 2004, Pages 629-636

  Getachew, Y ^a   Browning, J D ^a   Prebis, M ^b   Rogers, T ^a,b   Brown, G R ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; AGED; ALCOHOL CONSUMPTION; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GENOTYPE; GOUT; HEARING LOSS; HEPATITIS C; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; INFECTION; INTERMETHOD COMPARISON; KNODELL SCORING; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SOLDIER; TREATMENT WITHDRAWAL;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MIDDLE AGED; RIBAVIRIN; TREATMENT OUTCOME; VETERANS;

EID: 4644327961     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02095.x     Document Type: Article

References (34)

1. Reichard O, Norkrans G, Fryden A, et al. for the Swedish Study Group. Randomized, double blind, placebo-controlled trial of, interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-7.
2. Schalm SW, Hansen BE, Chemello L, et al Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic, hepatitis C. J Hepatol 1997; 26: 961-6.
3. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. NEJM 1998; 339: 1493-9.
4. Fontana RJ, Walsh JM, Moyer CA, et al. High-dose Interferon alfa-2b and ribavirin in patients previously treated with interferon: results of a prospective, randomized controlled trail. J Clin Gastroenterol 2002; 34: 177-82.
5. Ferenci P, Stauber R, Rudolf B, et al. Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. Euro J Gastroenterol Hepatol 2001; 13: 699-705.
6. Marco VD, Ferraro D, Almasio P, et al. Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction. J Viral Hepat 2002; 9: 354-9.
7. Malaguarnera M, Laurino A, Di Fazio I, et al. Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C. J Interferon Cytokine Res 2001; 21: 273-8.
8. Dwight MM, Kowdley KV, Russo JE, Ciechanowski PS, Larson AM, Katon WJ. Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res 2000; 49: 311-7.
9. Fontana RJ. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis 2000; 18: 107-16.
10. Scalori A, Apale P, Roffi L. Psychological screening before interferon therapy. Hepatology 2001; 33: 480.
11. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alpha, and depression. Hepatology 2000; 31: 1207-11.
12. Mulder RT, Ang M, Chapman B, Ross A, Stevens IF, Edgar C. Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C. J Gastroenterol Hepatol 2000; 15: 300-3.
13. Morelli J, Willner IR, Kim CY, et al. US veterans' experience with rebetron in a nonstudy environment: success or failure? Am J Gastroenterol 2002; 97: 2379-82.
14. Lehman CL, Cheung RC. Depression, anxiety, post-traumatic stress, and alcohol-related problems among veterans with chronic hepatitis C. Am J Gastroenterol 2002; 97: 2640-6.
15. Cawthorne CH, Fimmel C, Rudat KR, et al. Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol 2002; 97: 149-55.
16. De Vires M, Bleijenberg G, Soetekouw PM, et al. The role of post-traumatic stress disorder symptoms in fatigued Cambodia veterans. Mil Med 2002; 167: 790-1.
17. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
18. Carithers RL, Zeuzem S, Manns MP, et al. Multicenter, randomized, controlled trial comparing high dose daily induction IFN plus ribavirin vs. standard IFN plus ribavirin (abstract). Hepatology 2000; 32: 317A.
19. Bjoro K, Bell H, Helium K, et al. Randomized trial of IFN induction and ribavirin vs. standard IFN and ribavirin for chronic HCV in previously untreated patients (abstract). Hepatology 2000: 32: 317A.
20. Nguyen HA, Ho SB, Miller AI, et al. Spectrum of disease in US veteran patients with hepatitis C. Am J Gastroenterol 2002; 97: 1813-20.
21. Heathcote EJ, Shiffman ML, Cooksley GE, et al. Peg Interferon alfa-2a in patients with chronic hepatitis C and cirrhosis. NEJM 2000; 343: 1673-80.
22. Kontorinis W, Jeffery GP, Garas G, et al. Outcome, tolerability and compliance of compassionate use of Interferon and ribavirin for hepatitis C infection in a shared care hospital clinic. Int Med J 2003; 33: 500-4.
23. Planas R, Bruguera M, Quer JC, et al. Induction therapy with interferon alfa-2a in compensated hepatitis C virus-related cirrhosis. Randomized, multicenter study. Med Clin (Barc) 2002; 118: 641-4.
24. Thevenot T, Poynard T, Regimbeau V, et al. Meta Analysis of Interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update. J Viral Hepat 2001; 8: 48-62.
25. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.
26. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
27. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004; 140: 346-55.
28. Crippin JS, Charlton MR, McCashland T, et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transplant 2002; 8: 350-5.
29. Thomas RM, Brems JJ, Yong S, et al. Infection with chronic hepatitis C virus and liver transplantation: a role for Interferon therapy before transplantation. Liver Transplant 2003; 9: 905-15.
30. Bressler BL, Guindi M, Tomlinson G, Heathcote C. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-44.
31. Russo MW, Freid MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003; 124: 1711-19.
32. Van Thiel DH, Anantharaju A, Creech S, et al. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol 2003; 98: 2281-8.
33. Evangelista LS, Doering LV, Dracup K. Usefulness of a history of tobacco and alcohol use in predicting multiple heart failure readmissions among veterans. Am J Cardiol 2000; 86: 1339-42.
34. Lang JP, Halleguen O, Vecchionacci V, Doffoel M. Reflection on the treatment on EMD in hepatitis C virus patients treated with Interferon alpha form a retrospective survey concerning 29 patients. Encephale 2003; 29(3 Pt 1): 273-7.